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Abstract: Background: The increase in pharmaceutical waste medicines is a global phenomenon and 
financial burden. The Circular Economy, as a philosophy within the pharmaceutical supply chain, 
aims to promote waste reduction, maximise medicines value, and enable sustainability within this 
supply chain (increasing circularity). Circularity strategies for pharmaceuticals are not currently 
implemented in many countries, due to quality and safety barriers. The aim of this study was to 
determine whether the application of circular economy principles can minimise pharmaceutical 
waste and support sustainability in the pharmaceutical supply chain; Methods: a detailed narrative 
literature review was conducted in order to examine pharmaceutical waste creation, management, 
disposal, and the application of circular economy principles; Results: the literature scrutinised 
revealed that pharmaceutical waste is created by multiple routes, each of which need to be 
addressed by pharmacists and healthcare bodies through the Circular Economy 9R principles. These 
principles act as a binding mechanism for disparate waste management initiatives. Medicines, or 
elements of a pharmaceutical product, can be better managed to reduce waste, cost, and reduce 
negative environmental impacts through unsafe disposal. Conclusions: the study findings outline a 
Circular Pharmaceutical Supply Chain and suggests that it should be considered and tested as a 
sustainable supply chain proposition. 
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1. Introduction 
The World Health Organization (WHO) defines pharmaceutical waste as undesirable 
pharmaceuticals, including expired, unused, spilled, and infected pharmaceutical products, 
medications, vaccines, and sera that are not required and should be disposed of appropriately [1]. 
The volume of pharmaceutical waste has increased primarily due to growth in the number of patients 
and prescriptions and the use and overproduction of medicines. The increase in unused, expired, and 
misplaced medicines contributes to medicine shortages, higher percentages of pharmaceuticals 
waste, and increased medicine disposal costs, and it is a growing concern globally requiring a 
systemic approach to its resolution [2]. 
According to the Pharmaceutical Services Negotiating Committee (PSNC), prescribing 
pharmaceuticals represents the second-highest cost in the United Kingdom (UK), after medical staff 
[3]. As of 2019, around $1.25 trillion USD had been spent on medicines globally, up from only $887 
billion in 2010. The spending on medicines is anticipated to increase to $1.59 billion by 2024 [4]. By 
2019, the UK had around £127 billion spent in healthcare [5]. Such figures indicate an extensive waste 
of resources in the healthcare system. This waste includes inappropriately prescribed medication, 
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which results in the overstocking of medications. Gebremariam et al. [6] reported that supply chain 
management and related variables were principal contributors to the generation of pharmaceutical 
waste. Likewise, poor storage conditions, storing medicines on the floor, the absence of specific 
stocking plans, poor climate control, and overstocking expired medicines can lead to significant 
medication spoilage [6].  
The last phase of the pharmaceutical waste is disposal, traditional burning or non-burning 
technique utilized. It is essential to note that, out of all pharmaceutical waste, only 15% is hazardous, 
whilst the remaining 85% is general [7]. Large amounts of prescribed pharmaceutical waste are found 
in the waterways, streams and groundwater, and it has similarly been shown that a percentage of 
these are affecting the water and the climate [8]. The WHO classification of different types of 
healthcare waste is [7]:  
• pathological; this includes body parts, body fluids, human waste, and tissue waste and animal 
corpses that are contaminated; 
• pharmaceutical; this is either unused, contaminated medicine or medicine which has expired; 
• cytotoxic; genotoxic waste (highly hazardous); 
• sharps; includes syringes, needles, and blades, etc.; 
• infectious; this usually contains blood or any bodily fluid which is contaminated and could, 
therefore, infect other people when they come into contact; 
• non-hazardous; these waste materials can not cause any chemical, radioactive, biological, or 
physical dangers; and, 
• radioactive; products that are infected by radionuclides. 
These different types of waste require differing methods of disposal and/or new approaches in 
order to reduce or eliminate waste. It is important to determine the most suitable method to help 
preventing/reducing the negative consequences of the disposing methods on the environment, 
specifically on water, soil, air, and on human well-being [7,8]. 
The circular economy (CE) is a holistic philosophy that is conveyed through a system for 
managing and preserving resources ‘in use as long as possible through recovery and reuse’, hence 
circularity [9]. The CE approach closes the gap between production and the life cycle of the natural 
ecosystem upon which individuals rely for business and physical survival. It signposts practical ways 
of eliminating waste, transforming biodegradable and non-biodegradable waste, and promoting 
reuse and recycling. In CE, a distinction is made amongst different choices of circularity, represented 
as the R-model of 3R, 4R, or even 9R models (the 9R model being the optimal application of CE 
incorporating Refuse, Rethink, Reduce, Reuse, Repair, Refurbish, Remanufacture, Repurpose, 
Recycle, and Recover)[10,11]. Kirchherr et al. [12] claimed that the CE is ‘the combination of reduce, 
reuse and recycle activities’ to ensure systematic change. The CE has been rapidly growing to realise 
the United Nation Sustainable Development Goals (SDGs) and as an alternative strategy for business 
advancement. In the CE, products and services operate in closed loops (being produced and then 
recycled for further use) and they are intended to work in harmony with the environment. The Ellen 
MacArthur Foundation, which was founded in 2010 and aims to accelerate progress towards a 
regenerative CE [13], defines the CE as a move from a linear model of resource consumption, which 
pursues a take-make-dispose design, to an economy that is restorative by intention. The CE associates 
the supply and demand of supply chain industries in order to increase resource efficiency and help 
achieve sustainable production and consumption [11].  
Sufficiency economy philosophy (SEP) is another approach that has been considered in 
academic circles as contributing to the sustainability agenda. SEP is defined by the United Nations 
[14] as “an innovative method for development that is designed for practical application over a wide 
range of problems and situations”. The objective of SEP is to improve planning procedures in order 
to ensure sustainability, manage changes in the world and utilise natural resources in a capable way 
while preserving nature. SEP is a sustainable development approach that was introduced by the late 
king of Thailand and implemented through three different components; moderation, which aims for 
the effective consumption of resources; reasonableness, which concerns objectively choosing the 
degree of products adequacy while considering the elements that are involved and the normally 
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expected results; and, risk management, which entails adapting that is based on reasonable effects 
and changes that are projected by considering the likelihood of future circumstances from different 
viewpoints [15].  
A key objective of the CE is to promote and facilitate greater sustainability. A sustainable supply 
chain is defined as a supply chain, in which operations, assets, data, and funds are managed to 
increase supply chain production while simultaneously reducing environmental effects and 
improving social wellbeing [16]. As mentioned by the European Union (EU) parliament [17], the 
application of CE practices for waste management in general could help to save EU organisations 
nearly €600 billion through, for example, waste avoidance, eco-friendly products and reuse 
programmes. It could also help minimise yearly greenhouse gas emissions by 4%. The benefits of the 
CE include improvement of the environment, improvement of the safety of raw materials, 
acceleration of innovation, and improvement of economic growth [18,19]. 
An example of the CE in practice can be seen in closed-loop supply chains, in which recyclers 
and manufacturers collaborate and work closely to realise resource and cost savings. Many sectors 
have adopted closed-loop supply chains in their processes. In the medical field, GE Motors and 
Philips [20,21] have started to refurbish medical products, including magnetic resonance imaging 
(MRI), computed tomography (CT), ultrasound, and X-ray machines, by obtaining full control to 
guarantee that all exchanged materials are repurposed or reused and produced with high quality to 
ensure the efficiency of the products.  
The aim of this study was to determine whether the application of CE principles reduce 
pharmaceutical waste and support sustainability in the Pharmaceutical Supply Chain (PSC). The 
rationale of the aim of this research was to identify ways to decrease the negative environmental 
impact, costs and promote sustainable supply chain and eco-design through the application of CE 
principles in the PSC. By identifying how the CE principles and the R-strategies can be used in the 
pharmaceutical supply chain it will be possible to determine how the negative impact of 
pharmaceutical waste be reduced in terms of costs, sustainability, and increasing circularity. To 
achieve this aim, the following objectives were posited: 1) to ascertain how pharmaceuticals waste is 
created, 2) to better understand how this waste is managed, 3) to outline how it is safely disposed, 
and 4) to determine how pharmaceuticals waste can be reduced and better managed through the 
adoption of CE principles. 
2. Materials and Methods  
A review of current pharmaceutical waste management studies was undertaken to document 
how pharmaceuticals be reused and whether implementation of the CE philosophy and associated 
principles could help to reduce waste. The following keywords were used for the primary search: 
‘Medicines’ AND ‘Pharmaceutical’ AND ‘Pharmaceutical Waste’ OR ‘Drugs’ OR ‘Pharmaceutical 
Return’ OR ‘Disposal’ OR ‘Hospitals’ OR ‘Pharmaceutical Supply Chain’ OR ‘Medicines Reuse’ OR 
‘Circular Economy’ OR ‘Circular Economy Principles’. 
First, the titles and abstracts of each article were screened, and the most significant articles were 
selected. Second, the related abstracts were chosen, and the full form of each selected article was 
retrieved. A few papers were eliminated after their selection, as described below. Journals and papers 
published in English were chosen. Articles, papers, and studies published before July 2020 were 
explored while using Elsevier, Google Scholar, MDPI, PubMed, SAGE, and Science Direct. 
To be included in the review, articles/papers had to be related to pharmaceuticals, medicine 
reuse, waste management, and/or CE, and they had to present new and/or relevant information. 
Articles/papers on approaches to waste management improvement, legislation, the PSC, waste 
generation minimisation, and CE application were also included. Excluded papers are not explicitly 
relate to the keywords highlighted above. 
The search was conducted while using electronic databases, avoiding manual exploration. 
Duplications were eliminated. Non-academic grey literature was also searched in Google utilising 
similar keywords. These sources included journalistic articles, reports, and webpages on 
pharmaceuticals waste and CE. A conventional quality examination was not utilised, as one of the 
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goals of this study was to gather a broad base of proof, including all of the procedures and studies 
related to gathering in-depth literature data. Figure 1 shows the areas of the literature that were 
reviewed to meet the aim of this study. 
 
Figure 1. Areas of literature discovery. 
3. Results 
3.1. Pharmaceutical Waste Management 
The literature review identified three clearly defined areas of focus when examining 
pharmaceutical waste management. These are discussed individually below. 
3.1.1. Waste Creation 
Instances of pharmaceuticals waste may be caused by patients who are unable to utilise all of 
their administered pharmaceuticals due to unfavourable impacts (side effects), daily dosage 
modifications, health improvements, the expiry of medicines, doctors’ prescribing practices, or 
dispensers’ practices. Non-adherence to prescriptions can also cause stockpiling of leftover 
medications in the home. According to the WHO, half of the patients neglect to take medication 
effectively [22]. As such, families and patients around the world are in possession of unused or 
terminated prescriptions, and the associated dangers have prompted research interest. Many 
individuals who stockpile undesirable, unused, or expired pharmaceuticals in their homes dispose 
of them through waste containers or sinks or by flushing them down the toilet. It is important to 
realise that discarding unused or terminated pharmaceuticals through non-permitted methods 
affects the environment and individual wellbeing [6,23].  
Table 1 shows the different waste creation of pharmaceuticals. 
Table 1. Waste creation point and issues associated. 
Waste Creation Point Issue Current Resolution/Practice 
Manufacturing 
Overproduction of stock 
based on forecasted 
demand. 
Secure accurate demand based on 
transparency and sharing of information 
across the supply chain facilitated by 
government bodies [24,25] 
Overproduction of stock 
based on actual demand, 
e.g., a medicines shortage 
(but short lived so excess 
stock is created). 
Ensure the transparency of stock 
production and use and effective 
reporting of medicines shortages between 
pharmacies, wholesalers, and 
manufacturers [24] 
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Distinguish the cause of the shortage and 
focus efforts there to increase or use on-
hand supply [24,25] 
Pharmacy 
Overordering of stock by 
pharmacy. 
Implement effective procurement training 
and inventory management systems [26] 
Insufficient storage 
conditions by pharmacy. 
Conduct regular checks ensure suitable 
conditions of light, humidity, ventilation, 
temperature, and security [26] 
Hospital 
Wards/Clinics/Estates 
Excess stock requested and 
held by wards or clinics.  
Create stock lists at the ward level with 
the support of pharmacy store teams to 
manage stock levels of wards effectively 
[27] 
Incorrect medication 
prescribed for patient and 
not enough or unclear 
information given. 
Enact effective processes to process and 
dispense prescriptions supported by 
accurate information from a consultant to 
avoid irrational medication. Also, ensure 
that clarification is offered to the patients 
regarding the dosage, use, and 
advantages and disadvantages of the 
recommended pharmaceutical [28–30] 
Patient is deceased but 
medication is in their name 
and cannot be used by 
anyone else. 
Reuse prescribed medications if the 
patient is deceased. This applies if, for 
example, there is no available stock, no 
available alternatives, and there is no risk 
associated with other patients using the 
medicines [31,32] 
Medicines not rotated or 
used effectively (manual 
intervention based on expiry 
dates) or inventory 
management systems not 
utilized effectively to reduce 
stock obsolescence. 
Provide effective training for staff and use 
of inventory management systems [26] 
Patient’s own medicine lost 
on admission and, therefore, 
are not available for use. 
Encourage patients to bring their own 
medicines. Design system to ensure 
patients’ own medicines stay with them 
using green bags, e.g., the green bag 
scheme for improving the utilization of 
prescriptions for better results and 
decreased waste [29,30] 




segregation and disposal. 
Create dedicated resources to support 
pharmaceuticals waste management and 
safe disposal [33] 
Both small-scale (e.g., training programs) 
and large-scale (e.g., legislative and 
administrative) solutions are needed to 





Undertake informed prescribing in 
relation to quantity and frequency, guided 
by current data on stock availability 
provided by government bodies [35,36] 
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Develop a system to permit patients to 
improve their overstocking and ordering 
of medication [35,36] 
Remote prescribing by GPs. 
Remote prescribing are applied care 
home. But is being addressed with the 
introduction of pharmacists to manage 
prescriptions more effectively [37–39] 
Care Homes 
Excess stock received and 
held for patients. 
Educate staff to contact GP regarding 
prescribing patterns and use a pharmacist 
to support medicines use [31–40] 
Patients 
Repeating prescriptions 
requested by patients. 
Educate and facilitate patients to request 
stock when needed and approved by GP 
without overstocking [34–36,40]  
Advising GP or healthcare 
professional when they 
cannot take medicines and 
no longer needed. 
Educate and facilitate medicines returns 
to pharmacy, GP, or another reliable 
repository [38] 
Unused pharmaceuticals could be the result of changes in the recommended treatment. Such 
practices lead to the expiration of prescriptions, which are then put away or discarded by household 
members who flush them down toilets instead of returning them to pharmacies [39]. Analysis 
indicates that £300 million worth of prescription pharmaceuticals that are authorised by the UK 
National Health Services (NHS) are wasted every year [41]. Such wastage accounts for a significant 
percentage of pharmaceutical-related expenditures in the UK. For every £25 spent on pharmaceutical 
products, £1 is wasted. The £300 million includes £90 million worth of unused prescriptions in 
people’s homes at any one time. An estimated £110 million worth of prescriptions are returned to 
pharmacies every year. Approximately £50 million worth of unused pharmaceuticals from care 
homes are disposed of every year by NHS [41]. 
The UK government funds its healthcare system through taxation of its citizens and businesses. 
Pharmaceutical waste increases the cost to the government of meeting the healthcare needs of the 
country. At the same time, pharmaceutical waste that results from non-adherence to prescribed 
medications increases the cost of treatment, because patients subsequently require additional 
treatment [42]. An increase in unused and expired medicine contributes to pharmaceutical waste and 
increases the use of financial resources [43–45]. Although unused pharmaceuticals have been studied 
extensively worldwide, there are obstacles to decreasing the number of unused pharmaceuticals. 
Leftover medicines in hospitals may expire and remain unused, because of a lack of proper controls 
[44,45]. Most hospitals experience increased pharmaceutical waste as a result of poor dispensing 
strategies by the pharmacy, which contributes to the overflow of pharmaceuticals [45]. 
Another reason for increased pharmaceutical waste is a lack of knowledge regarding medication 
usage and disposal [46,47]. Patients may not be educated as how best to safely dispose of their 
medicines. Another reason for unused medicine may be changes in treatment, meaning that the 
unused medications become a source of waste [46]. 
3.1.2. Waste Management 
Current pharmaceutical waste management and disposal methods and related social, economic, 
and environmental burdens must be understood from different points of view [48]. The lack of 
awareness of proper waste management in hospitals, particularly those in developing countries, has 
made these institutions a focal point in the spread of disease and infection, rather minimising and 
eliminating waste [48,49]. Research on hospitals in Kuwait found that pharmacists lacked knowledge 
about the consequences of sub-optimal/unsafe pharmaceutical disposal methods and often did not 
follow guidelines that were issued by the Ministry of Health [49]. A similar study [47] on Iraqi 
hospitals found that pharmacists needed programmes to improve their knowledge of appropriate 
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disposal methods for pharmaceuticals waste. Inadequate training and a lack of awareness among 
hospital staff, such as nurses and pharmacists, contribute to the increase in pharmaceutical waste in 
many countries. Control and visibility are crucial in the reduction of losses due to expiry. When the 
inventory system is functioning at optimal levels, inventories could be redistributed within the 
system in order to enable a quick workflow.  
Johnson et al. [50] found that the inadequate segregation of waste increases costs to hospitals 
already under significant budget constraints. There is much misunderstanding regarding the best 
possible methods of medication disposal, and several countries do not have standard medication 
disposal requirements. For decades, there have been various reports about the presence of 
pharmaceuticals in groundwater, lakes, waterways and drinking water due to improper disposal 
[22]. These pharmaceutical disposal methods negatively affect natural ecosystems and human health. 
Against this backdrop, there is a need to effectively manage waste and focus on avenues to 
control or decrease waste creation. Waste management practices are currently undergoing significant 
changes from a simplified collection and sorting procedure to a sustainable smart waste management 
system, as per Zhang et al. [51]. This is achieved by effectively managing and focusing on 
product/service system designs, resource and energy recovery and end-of-life management of 
currently wasted resources through initiatives, such as waste reduction practices, biological and 
thermal processes, and material recycling techniques. 
Significant efforts are underway in order to reduce pharmaceutical waste, not just for financial 
reasons but also to address issues related to current pharmaceutical waste disposal methods, such as 
landfills [52]. Returned medications are treated as waste and disposed of or destroyed [53]. Reuse 
and recycling remain generally unexplored, because, under current regulations, many countries, 
including the UK, do not allow for unused or returned medications to be reused or to enter the PSC 
[54]. 
Better waste management can be achieved by focusing on improving the efficiency throughout 
the value chain in terms of the production, inventory management, usage/consumption, and 
performance of resources. There is also a need to change the waste management approach by 
introducing waste management plans that enable facilities to plan for all necessary resources, 
including staff training; to monitor and evaluate the waste generated from the facilities; and, to take 
charge of all activities that are likely to generate waste [55]. In addition, waste management also 
requires effective segregation of waste, which is key to reducing the volume of waste that needs 
attention and ensuring that each treatment process only receives compatible waste [55]. The 
introduction of a digital track and trace system would provide timely information to support the 
production and distribution of medicines in order to optimise medicine production and reduce 
overproduction, which leads to the generation of waste [55–57]. 
A large amount of waste is generated when there is lack of visibility of waste generation by the 
hospital management. Capturing data usage and using that in supply chain management is critical 
for reducing waste [58]. Tracking utilisation ensures that a facility only has what it needs without 
excesses or wastage. A balance must also be maintained between what gets produced, ordered, and 
distributed. Forecasting is critical in maintaining a balance in the healthcare management system. 
Pharmaceuticals waste is currently managed and processed in multiple ways, and all stakeholders, 
e.g., manufacturers, general practitioners (GPs), pharmacy, care homes, and patients, in the 
pharmaceuticals waste management context play roles in waste management, treatment, and 
disposal.  
3.1.3. Waste Disposal 
Studies on household pharmaceuticals in Ethiopia [59], Kuwait [60], Poland [61], Saudi Arabia 
[62], Qatar [63], the UK [64], and the United States [65] concluded that most unused and expired 
pharmaceuticals are disposed of in the garbage, as there is no clear guidance for patients on the 
proper disposal of medications. The causes of medication wastage are different in each household. 
The death of a patient, changing from one medication to another, stopping treatment and lack of 
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consistent use by patients all contribute to pharmaceutical waste [59–65]. Continued pharmaceutical 
waste over time significantly impacts the environment [8]. 
The Basel Convention recommends that all healthcare organisations follow waste treatment 
methods that reduce the release of chemicals or hazardous waste [66]. Likewise, the WHO 
recommends following waste treatment methods that help to reduce the release of chemicals while 
recognising the differences in local conditions and availability. To a large extent, poor disposal 
practices are often due to an absence of adequate training for clinical staff. Insufficient hospital 
funding also leads to improper waste disposal [60–62]. Table 2 shows the advantages and 
disadvantages of different pharmaceuticals waste disposal methods. 
Table 2. Medicines waste disposal methods. 
Treatment Advantages Disadvantages 
Incineration 
[67] 
Low cost, accepts different waste types, 
minimises the waste volume 
Not environmentally friendly, 
increases pollution, high cost 
Autoclaving 
[68] 
Environmentally friendly, used for 
infectious waste and sharps 
Does not minimise the volume and is 




No combustion or gasification, minimal 
emissions Not applicable for all waste, high cost 
Pyrolysis [69] 
Environmentally friendly, disposes of all 
kinds of waste, minimises the waste 
volume 
High cost, requires certified 
professional workers 
Landfill [68] Low cost Not environmentally friendly, 
increases health risks 
Recycling [70] Environmentally friendly, reduces cost Not all types of waste can be recycled 
Landfills and incineration are the two most utilised disposal strategies [71]; these alternatives 
for the final removal of waste are utilised to various extents worldwide. In every country, 
geographical, economic, social, technical, and other factors must be considered when selecting 
preferred waste disposal methods. In the EU and Japan, incineration is viewed as the preferable 
method of pharmaceutical waste disposal, and landfills are considered to be a last resort.  
Final safe disposal of pharmaceuticals waste is critical, given the potential public health risks 
that are associated with this type of waste. The most effective way to minimise and dispose of 
pharmaceuticals waste is to separate waste at the generation stage [72]. It is important to separate 
waste streams in the workplace to protect people and the environment, regardless of the disposal and 
treatment strategy. Separation involves sorting various types of waste while using liners with 
different coloured codes or original packaging in which they are produced. This has regularly been 
the main task of pharmaceuticals waste disposal. The lack of adequate separation of pharmaceuticals 
waste increases the risk of workplace accidents and blood-borne viral infections [73]. 
Pharmaceutical disposal methods need to be adhered to properly, and pharmaceuticals should 
be returned to a predetermined pharmacy controlled by the health ministry [31]. Pharmaceutical 
waste disposal frameworks are available in certain nations, and many countries follow the same 
framework in dealing with returned or expired medications. In the UK and New Zealand, individuals 
are advised to return expired and unused medications to the pharmacy for safe disposal and they are 
advised never to dispose of them down toilets [31,33]. In the United States, a system for managing 
pharmaceuticals waste removal has been developed under the regulations of the Food and Drug 
Administration (FDA) and the Environmental Protection Agency (EPA) [74]. Australia has 
implemented a programme (NATRUM) that accepts returned and unwanted medicines for free [75].  
3.1.4. Waste Reuse and Recycling 
Current methods of disposing of unused pharmaceuticals, including expired pharmaceuticals, 
have become a global issue. Take-back programmes for pharmaceuticals are eco-friendly and they 
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have been implemented in many countries, as discussed by Alnahas et al. [48]. The objective of these 
programmes is to safely dispose of pharmaceuticals returned by patients who no longer need them. 
Many countries do not permit returned medications to be re-dispensed. For example, the UK requires 
disposal, even if the medications are in good condition and have not been used. However, a study of 
pharmaceutical reuse in the UK concluded that, based on the findings of the interviews data, reusing 
unused medicines would reduce NHS spending and lower manufacturing costs [46].  
The United States and Greece allow for medications to be reused to make medicine more 
affordable for people who would not otherwise be able to pay for them [76]. These programmes 
involve the collection and reintroduction of medicines to the original processing location to be 
recycled or reused by the government, retailers, or manufacturers. For instance, SMARXT Disposal, 
a partnership between the American Pharmacists Association, Pharmaceutical Research and 
Manufacturers of America and Fish and Wildlife services, has developed awareness campaigns for 
take-back initiatives that involve a collaborative structure for pharmaceuticals waste reuse [77]. This 
programme helps to reduce the cost of pharmaceuticals and improve the efficiency of the supply 
chain. Similar programmes have been initiated around the world: in Canada, the ENVIRx 
programme accepts unused and expired medication for proper disposal; New Zealand adopted the 
Disposal of Unwanted Medicines Properly (DUMP) programme to encourage individuals to return 
unused and expired pharmaceuticals; and, in Australia, the Return Unwanted Medicines (RUM) 
programme was adopted for proper disposal [78,79]. 
When medicines are returned to physicians, they are destroyed according to guidelines that 
operate on the assumption that these end-of-life items are useless, as mentioned by Breen [80]. This 
process could be improved by collecting information about the returned products from GPs, 
pharmacists, administration improvement managers, and commissioners. Information, such as the 
amount prescribed, to whom it was prescribed and when it was administered, could be utilised in 
order to improve prescribing, minimise waste and improve medicine optimisation [80]. 
Open medicines return events can be jointly held by pharmacies and local councils to help 
spread awareness in communities about the importance of returning medicines so that they can be 
destroyed according to government guidelines. These events can help to minimise pharmaceutical 
waste and increase recycling and the proper disposal of medication [81]. They can also help to 
increase awareness regarding how following appropriate procedures helps minimise environmental 
effects [81]. Raja et al. [82] proposed that governments develop and implement a national medication 
return programme to gather unused or terminated medications at each hospital, so that they can be 
disposed of properly. Improving the pharmaceutical waste management system and achieving a 
green PSC requires the cooperation of the entire supply chain from the manufacturers and wholesale 
suppliers to the GPs, community pharmacies, and patients.  
Research that was conducted by Hsieh et al. [83] indicates that the lifespan of specific Active 
Pharmaceutical Ingredients (API) can be extended where APIs from medicines can be recovered and 
reused for new formulation development if they do not contain excipients. The recovery process can 
be done using green engineering, a technique that uses water for the separation process and 
mechanical energy to provide the power for membrane separation. The process used are tablet 
milling and dissolution, solid-liquid separation, diafiltration by ultrafiltration, reverse osmosis 
membrane operation, and crystallization. The recovery process helps to reuse of the API and 
minimize the cost of API production [83]. Some important points need to be considered for the 
recovery process [84]. The purity of the reused API should be close to that of a new API, which 
includes, for example, its density and flowability, while the concentration of the polymer that is 
recovered should be insignificant, making sure that chemical degradation is avoided by using a 
suitable temperature during the process, and avoiding any harmful chemicals in order to ensure a 
low-cost green process [84]. The API recovery cycle is considered to be green because any solvents 
from waste are completely recovered and reused.  
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3.1.5. Obstacles to the Safety and Quality of Returned Pharmaceuticals 
Regulatory agencies must have strict quality control and safety monitoring measures in order to 
affirm the appropriateness of medications for reuse. Such procedures include monitoring by 
specialists to confirm the capacity and limit any risk of damage, contamination, or infection. 
Moreover, the proper reuse and recycling of medications can reduce the environmental impacts of 
improper or illegal disposal of pharmaceuticals and reduce the associated carbon footprint. 
Table 3 identifies some barriers to the safety and quality of returned medications, which may 
affect redistribution. The safe disposal of medicines determines the standards of quality in the PSC. 
Health and safety are essential factors to consider in the PSC in order to protect consumers from 
infections, complications, and side effects from medications, as well as death due to improper 
medication usage. 




Returned medicines may have been subject to intentional tampering, e.g., incorrect 
packaging. 
Some presently utilised seals on external medication packaging lack careful designs 
and effectiveness. 
Packaging may be unsealed. 
Packaging may have been contaminated while in a patient’s possession. 
Quality 
[2,31,76,85] 
Medicines may have been stored in undesirable conditions, e.g., temperature, 
moisture, light. 
Medicines may have an undesirable smell. 
Counterfeit medicines via a redistribution scheme. 
The dispensing and expiration dates may affect the quality of the medication. 
The decision to reuse returned pharmaceuticals depends on a safety confirmation process, 
whereby devoted analysers at pharmacies can process unopened, intact, and authentic 
pharmaceuticals. Using technology and engaging arranged networks in smart pharmaceutical 
packaging will help to determine whether returned, unused, and unexpired medications are safe for 
reuse [57]. 
Huge strides have been made in the design of secure pharmaceutical packaging in ensuring trust 
and confidence in the integrity of medication [2,86–88]. This advances further support the global 
Falsified Medicines Directive launched in 2019, which ensures product integrity within the supply 
chain from the point of production through to customer sales [89]. Product protection within the 
supply chain was reinforced in 2018 when the International Organization for Standardization (ISO) 
published the new ISO standard 21976:2018, entitled "Packaging-Tamper verification features for 
medicinal product packaging", and again in 2019, when pharmaceutical companies that have 
prescription medicine in their portfolio were required in order to provide additional security features 
in accordance with the Anti-Counterfeiting Directive 2011/62/EU [90]. Stakeholders within the 
pharmaceutical supply chain need to know that medication has not been tampered with or affected 
by transportation/storage conditions. These developments in policy, along with high-tech tamper 
proof solutions and innovative pharmaceutical packaging that provides patients with clear 
instructions, prevents harm to the environment and conforms to government guidelines and 
strategies, support the premise that medication could be reused [2,91,92]. 
3.2. Circular Economy and the Management of Pharmaceutical Waste 
When considering the application of CE principles to the PSC, the best methods for reducing 
pharmaceutical waste include reducing, reusing, and recycling disposable instruments and materials. 
CE offers several advantages to healthcare services, including cost savings, high quality of life, and 
continual service improvement [93]. Pachauri et al. [94] found that the CE promotes the use of 
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sustainable products by replacing nonbiodegradable raw materials. The entire operational process is 
interlinked to accomplish sustainability, as the waste and products of one phase become the raw 
materials for other products or procedures.  
As stated earlier in this discussion, the basic principles of CE are the three Rs; Reduce, Reuse, 
and Recycle. Examples of the application of these principles can be seen within the PSC. However, 
the more advanced principles of CE extend past the 3Rs and they present a stronger proposition, 
which are the 9Rs (see Table 4) [95]. Each R prompts product owners to focus on their creation, use, 
and disposal, in order to expend their lifespan, but where feasible also maximise the use of materials. 
This, is turn, contributes to the United Nations Sustainable Development Goals, to end poverty, 
protect the planet and ensure that all people enjoy peace and prosperity by 2030 [96].  
Table 4. 9Rs Circularity strategies [95] (adapted by author). 
 R-Strategies Aim 




Make product redundant by abandoning its 
function or by offering the same function 
with a radically different product.  
(1) Rethink Make product use more intensive (e.g., by 
sharing product).  
(2) Reduce 
Increase efficiency in product manufacture or 
use by consuming fewer natural resources 






Reuse by another consumer of discarded 
product which is still in good condition and 
fulfils its original function.  
(4) Repair Repair and maintenance of defective product 
so it can be used with its original function.  
(5) Refurbish Restore an old product and bring it up to 
date.  
(6) Remanufacture Use parts of discarded product in a new 




(7) Repurpose Use discarded product or its parts in a new 
product with a different function.  
(8) Recycle Process materials to obtain the same (high 
grade) or lower (low grade) quality.  
(9) Recover Incineration of material with energy 
recovery.  
There are a number of excellent examples in the pharmaceutical supply chain where innovative 
practices are in place in order to promote the reduction of waste creation (reduce), to enhance the 
reuse of medication where legal and possible (reuse), and recycle products or product components 
where legal and feasible (recycle). These clearly support the CE ethos. Table 5 illustrate some 
examples of the practices.  
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Table 5. Examples of current pharmacy medicines waste management practice that endorses the 




Consideration of how medicine donations from medicinal 
services and patients could help reduce waste and increase 
the reuse and recycling of medicines. These medicines could 




Extension of the product’s lifecycle, as prompted by medicine 
shortages. 
Falsified Medicines Directive 
(FMD) and Support of Anti 
Counterfeit Technologies 
[101] 
The introduction of FMD and the adoption of technologies to 
reduce counterfeit drug presence in the supply chain. This 
increases the transparency of stock, increases confidence in 
stock integrity and reduces risk of patient harm.  
Inhalers 
[102,103] 
Promotion of more environmentally friendly inhalers and 




Based on group volume, offering clinics to share vials of 
medications, ensuring maximum utilisation of stock and 
reducing waste and cost. This also positively impacts stock 
creation and holding within the supply chain due to the 




Consideration of a practice of prescribing medicines in 
specific quantities and frequencies, which can smooth out the 
demand for specific medications, reducing the risk of shortage 
and domestic stockpiling. This practice could also promote 
the equity of access to medication. 
Return Schemes for 
Medication Reuse 
[46,104] 
Verifying the safety and quality of returned medications and 
ensuring that medicines have tamper evident packaging to 
help endorse the reuse of medication scheme. 
Return Schemes for Safe 
Disposal 
[79] 
For example, DUMP schemes, where patients are encouraged 
to remove unwanted products from their homes to reduce 
risks to patient and family safety and reduce potential 
environmental harm.  
API Recovery for Reuse 
Green engineering technology to recover and reuse the API 
(extracting, purifying, and repacking) can help to minimize 
waste and provide it value again [48,83].  
At present, the used substances are considered to be obsolete, infectious, and harmful to society 
and the environment [105]. However, easing strict guidelines in pharmaceutical reuse could pave the 
way for strengthening circular principles in the healthcare economy [105]. Connelly [76] argued that 
this could also help pharmacists re-dispense returned medicine to other patients who need treatment, 
helping to reduce pharmaceutical waste in health facilities.  
Recently, in response to the COVID-19 pandemic, the NHS in the UK released guidance for 
reusing medications in assisted care homes and hospices [106]. The government choice to reuse 
pharmaceuticals under strict governing criteria is an attempt to manage medical deficiencies and 
shortages during this period only. All of the prescriptions not required by the individual for whom 
they were initially prescribed can be reused under the management of registered healthcare 
professionals and proper recordkeeping [32]. However, some patients may not accept returned 
medication, citing concerns regarding the proper storage of unused medicines, e.g., room 
temperature, humidity or sanitation [8]. The reuse of medications to treat different patients during 
pandemic is especially feasible in cases where patients no longer need the drug, e.g., if they have 
died, or the provision of their medicine has been interrupted. Reuse applies to all medications—
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including fluid prescriptions, injections (analgesics, insulin), creams, and inhalers—that are in sealed 
or closed packs [9,32]. 
When contemplating the adoption of the CE into the PSC, key factors that should be considered 
are presented in the Political, Economic, Social, Technological, Legal, and Environmental (PESTLE) 
model, which supports or challenges practice change. The following PESTLE analysis is proposed 
based on the literature reviewed in this study (Table 6). 
Table 6. Political, Economic, Social, Technological, Legal, and Environmental (PESTLE) analysis of 
the adoption of the Circular Economy in the Pharmaceutical Supply Chain (PSC). 
Criteria 
PESTLE Enablers Barriers Importance 
(P) 
[107–109] 
Tax incentives in the PSC positively 
support the CE.  
International agreements and 
collaborations lead to the 
enforcement of effective policies in 
the PSC. 
Government funding exists for CE 
projects. 
There is inadequate government 
funding to shift the PSC to the CE. 
There is no effective enforcement 
strategy to shift the pharmaceutical 
sector to the CE.  
The discriminatory implementation 
and establishment of PSC policies 
discourage the shift to the CE.  
Political factors 




through funding.  
(E) 
[80–82] 
Reduction in the use of 
pharmaceuticals leads to minimised 
costs.  
An increase in household healthcare 
expenditures creates a need to 
reduce the cost of production. 
There are pricing pressure in the PSC 
between different suppliers. 
The high cost of establishing the CE is 
challenged by the low revenues of the 
pharmaceutical industry.  
The current medicine taxation system 
is a barrier to the transition to the CE.  
The economy is 
a significant 
determinant of 
the running of 
the PSC because 
it guides supply 
and demand.  
(S) 
[46,109,110] 
New preferences in the population 
regarding the form of medications 
that are administered enable the shift 
towards the CE. 
Suppliers in the sector have a shared 
CE vision, which facilitates achieving 
it. 
There is resistance from internal PSC 
and society to change from linear 
production to the CE in the PSC.  
Insufficient information on the 
recycling and reuse of medicine and 
related benefits results in hesitation to 
change.  
There is an absence of technical skills 
in applying the CE in the PSC while 













Secure information sharing systems 
are needed within medication 
tracking systems.  
Technology makes it easier to engage 
with patients. 
Technology helps minimise the 
stockpile of medications on the shelf 
and efficiently manage the stock.  
Advanced medicine manufacturing 
technology supports the transition to 
CE.  
The cost of developing and applying a 
new advanced technology to transition 
to the CE is high.  
There is inadequate expertise in 
running the technical equipment 
needed for the CE in the PSC. 
The PSC relies 
on technology 
for production 
and efficiency in 
its operations.  
(L) 
[82,111,112] 
Proposals concerning the reduction 
of waste produced by 
pharmaceutical manufacturers 
support the CE. 
Regulations on standards of 
pharmaceutical distribution process 
support the CE.  
There is a lack of systems to measure 
and assess the CE in the PSC. 
There is a lack of effective legislation 
on poor waste management.  
The existing laws are not clear about 
pharmaceutical producers’ 
responsibility for waste management. 
The PSC requires 
legal regulations 
to guide supply 
chain operations.  
(E) 
[62–64] 
Pharmaceutical and biotech 
companies’ high levels of energy 
consumption drive them to seek 
There is a lack of adequately set 
strategies on the recycling and reuse of 
The PSC is a 
sector that must 
meet high 
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more eco-friendly means of 
operation.  
Emphasis that is placed on the 
benefits of recycling, reusing and 
reducing medicines supports the 
production of medicines in a CE.  
Needs to change the poor 
management of pharmaceutical 
disposal methods. 
medicine in an environmentally 
friendly way. 
Existing laws are not clear about the 
responsibility of the producers 
regarding waste management.  
Individuals’ awareness of proper 
medicine disposal is low. 
standards of 
quality, which 





In CE implementation, a definitive objective is to hold the essential value of items using an item 
for as long as might be feasible and in a closed loop, such as reuse and recycle. The most suitable path 
must be explored in terms of approaches and legislation in order to set up circular material 
dissemination in a closed circle and ensure the sufficiency of the production and consumption of 
pharmaceuticals. Progress towards CE implementation requires interactions between specialists, the 
legislation, the supply chain, production frameworks, and utilisation, which are controlled and 
characterised through authoritative, financial, and instructive instruments.  
4. Discussion 
It is clear from the literature presented above that there is a discerning focus on pharmaceutical 
waste management across multiple channels; however, what is not evident is a binding mechanism, 
a home for the disparate initiatives and practices to come together and make sense for the users to 
adopt when tackling pharmaceutical waste. We posit that the Circular Economy philosophy offers 
this.  
Officially, pharmaceutical waste management is an exceptionally specialised field that must be 
managed by qualified, skilled, and experienced staff at the administrative and ground levels. A large 
amount of waste is generated in healthcare institutions, due to a lack of proper systems, inadequate 
training, and a lack of balance between supply and demand within the healthcare inventory 
management system, which can increase financial and environmental issues. Proper measures should 
be taken, especially medicinal stock management, evaluation, quantification, procurement, and 
utilisation, in order to improve the supply chain and minimise waste. There are many examples of 
excellent practice that aspire to reduce, reuse, and recycle medicines, as noted in this study, but more 
needs to be done to maximise these efforts and offer clear steering on standardised methods that can 
be adopted and built into pharmacy practice. We see clear reference in this work to the basic 3Rs of 
CE, Reduce, Reuse, and Recycle, but endorsing CE in its entirety would prompt pharmacy, pharma, 
and healthcare professionals to consider the use of green product design, production, logistics, and 
dispensing to patients to move closer to the optimal 9Rs of CE. 
Pharmaceutical waste management can also be both exacerbated and more effectively managed 
by the actions of healthcare providers and patients by inappropriate prescribing, repeat medication 
requests, lack of compliance to medication regimes, and stockpiling, as highlighted earlier in the 
paper. Measures can be taken in order to identify sources of waste creation and take steps to address 
these to maximise product utilisation when in the system as a finished product, but also reduce 
additional risk to the patient, their families in their homes (by returning unwanted stock to 
pharmacies), and also the environment (using safe disposal methods). The role of the patient in 
supporting effective pharmaceutical waste management should not be underestimated.  
From a systemic approach, the adoption of the CE and associated principles can support waste 
reduction across the entire pharmaceutical supply chain. While reusing and recycling medicine helps 
to reduce pharmaceutical waste from environmental and economic perspectives, their application 
needs further improvement and approval by economic and government authorities and endorsement 
from all supply chain stakeholders. Moreover, it is important to redesign the current pharmaceutical 
product life cycle to facilitate medication reuse and minimise waste.  
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Four key aspects of creating a Circular PSC (CPSC) related to the internal mechanisms of 
associations and the duties of various PSC actors have been identified. Figure 2 shows how these 
aspects are interconnected and how they affect the implementation of the CPSC. 
 
Figure 2. Aspects of the Circular Pharmaceutical Supply Chain (CPSC). 
A set of legislative guidelines regarding the reuse of medicines must be set in order to limit 
wastage and introduce CE principles throughout the PSC, endorsed by all stakeholders. By resolving 
conflicting goals and involving all stakeholders, including packaging manufacturers, recyclers, 
decision makers, society, and consumers, pharmacists can legitimately and supportively influence 
patients’ understanding of proper medicine use and commitment to reducing waste generation 
through proper use and disposal. They can also educate their patients on medicine-related issues, 
such as proper medicine use, pharmaceuticals waste, and appropriate disposal and return methods 
for unused and expired medications. 
Thus, the use of the CE as a binding mechanism for existing and potential waste reduction 
practices can improve pharmaceutical waste management. Table 6 shows the changes needed related 
to moving from a linear chain (take, make, dispose) to a circular (proposed practice) PSC under an 
analytical level. Table 7 shows a systemic multi-level appraisal of practice changes that can be 
undertaken to move from a linear chain (take, make, dispose) to a circular PSC (proposed practice to 
expand product lifespan and material reuse). 
Table 7. Proposed changes needed to move toward a Circular PSC. 
Level of Analysis Focus Area Consideration for Change 
Meta Level (Global) 
E.g., WHO, UN, International 




Global recognition of pharmaceutical waste 
levels. 
Inclusion of waste reduction targets in 
global sustainability policy 
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Macro Level (National) 
E.g., government, 
suppliers/wholesalers, 













Endorsement of CE agenda in the 
pharmaceutical supply chain. 
Agreement to provide resources to target 
pharmaceuticals waste reduction 
Acknowledgment of the value of CE 
philosophy in the design of waste 
reduction policies and practices 
Financial support for innovative 
technologies to deliver green 
design/logistics 
Building awareness of the 3Rs of CE 
(reduce, reuse, recycle) into pharmacist 
education 
Design and delivery of awareness 
campaigns to healthcare professionals and 
patients (co-designed output) 
Meso Level (Organisational) 
E.g., hospitals, community 
pharmacies, GP, healthcare 
professionals 
System design and 
delivery 
Patient education 










approach to waste 
reduction  
Creation of efficient medicine management 
systems to minimize waste creation and 
ensure safe disposal 
Engage in patient education to raise 
awareness of medicine use and waste 
creation channels 
Design effective channels for medicine 
returns/collections 
 Dedicate time for medicine management 
training regarding ordering, storage, 
reuse/recycling 
Build teams to facilitate medicine stock 
management/retrieval from wards, conduct 
returns audits and safe disposal 
Identify champions to support 
pharmaceuticals waste reduction practices 
Micro Level (Individual) 







Awareness of medicine 
returns 




Engage in an educational campaign on the 
scale of pharmaceuticals waste and the 
financial, social and environmental 
repercussions associated with poor 
medicine management 
Adopt a personal responsibility to reduce 
pharmaceuticals waste as part of civic duty 
Work with stakeholders to design simple 
mechanisms to prompt medicine returns 
(e.g., text messages, flyers).  
The proposition is based on moving from the linear traditional approach of making products, 
use, and dispose, to (1) designing for potential future re-use (having components that can be 
remanufactured/reconfigured to be part of a new product e.g., inhaler cartridges); (2) making only 
what is needed; (3) using in a thrifty manner (both support SEP philosophy); (4) reusing 
products/components where possible (e.g., API extraction); (5) disposing in an environmentally safe 
capacity; and, (6) offering growth capacity in order to promote greener practices and a 9R agenda. 
Figure 3 shows the changes factors needed for CPSC. 
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Figure 3. Circular Pharmaceutical Supply Chain (CPSC). 
The limitations of this study are that it is theoretical and as such the conceptual model developed 
does need to be considered further and tested. Further research would be to undertake qualitative 
analysis with stakeholders in the PSC in order to determine their views on current waste management 
practices and the application of CE principles to the PSC and the adoption of CPSC. 
5. Conclusions 
This study aimed to determine whether the application of circular economy principles can 
minimise pharmaceuticals waste and support sustainability in the pharmaceutical supply chain. The 
results show that there are a multitude of practices that are used in order to reduce pharmaceuticals 
waste, but these are not always targeted or informed by any guiding principles or strategies. The 
CPSC as designed advocates that all stakeholders in the supply chain should contribute to effective 
management of medicines which includes design, production, use, reuse, and recycling (at its optimal 
level incorporating 9R practices). The following conclusions are proposed.  
In our exploration of the application of CE to the PSC and the conceptual model produced, the 
CPSC, we acknowledge that there are existing examples of CE in this supply chain, but these reflect 
the application of the 3Rs as opposed to the wider remit of CE, the 9Rs. How the 9Rs can be applied 
throughout the PSC is unclear at present.  
The success of the embodiment of the CPSC relies on both government and professional body 
endorsement and the recognition of pharmaceuticals waste management in pharmacist training and 
development. It also requires the inclusion of skills from other disciplines, e.g., engineering and 
management (for product/technology/systems development), in order to ensure greener thinking 
from product conception through to use and safe disposal by the patients. 
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